Connective tissue disease: Trial of SLE therapies in real-world settings

Nature Reviews Rheumatology

Volumn 8, Issue 3, 2012, Pages 128-130

  Ramos Casals, Manuel ^a   Khamashta, Munther A ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; EPRATUZUMAB; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; RITUXIMAB; STEROID;

ADVERSE OUTCOME; B LYMPHOCYTE; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; ETHNICITY; EVIDENCE BASED PRACTICE; GOVERNMENT REGULATION; HEALTH CARE QUALITY; HEREDITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIFE EXPECTANCY; LONG TERM CARE; OFF LABEL DRUG USE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; GLUCOCORTICOIDS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR TARGETED THERAPY; OFF-LABEL USE; PRACTICE GUIDELINES AS TOPIC;

EID: 84857918118     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.4     Document Type: Review

References (10)

1. Aringer, M. et al. Current state of evidence on "off label" therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria, and Switzerland-a consensus report. Lupus http://dx.doi.org/10.1177/0961203311426569.
2. Houssiau, F. A. et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial. Ann. Rheum. Dis. 69, 2083-2089 (2010).
3. Ginzler, E. M. et al. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: Findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum. 62, 211-221 (2010).
4. Griffiths, B. et al. The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology (Oxford) 49, 723-732 (2010).
5. Dooley M. A. et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 365, 1886-1895 (2011).
6. Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 377, 721-731 (2011).
7. Ramos-Casals, M., Sanz, I., Bosch, X., Stone, J. H. & Khamashta M. A. B-cell depleting agents in systemic lupus erythematosus. Am. J. Med. (in press).
8. Ad Hoc Working Group on Steroid-Sparing Criteria in Lupus. Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: Report of a consensus meeting. Arthritis Rheum. 50, 3427-3431 (2004).
9. Bertsias, G. et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann. Rheum. Dis. 67, 195-205 (2008).
10. Ramos-Casals, M., Díaz-Lagares, C. & Khamashta, M. A. B-cell-depletion therapy in systemic autoimmune diseases. Recommendations for use in clinical practice [Spanish]. Med. Clin. (Barc) 136, 257-263 (2011).